ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Trial Timeline
Jun 13, 2017 → Dec 4, 2023
NCT ID
NCT03117049About ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + Placebo
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + Placebo is a phase 3 stage product being developed by Ono Pharmaceutical for Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03117049. Target conditions include Non-Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03117049 | Phase 3 | Completed |
Competing Products
20 competing products in Non-Small Cell Lung Cancer